The investigation of hyaluronic acid and hyaluronidase‐1 levels as tumour marker in larynx cancer

Abstract

Objective The purpose of this study was to investigate the hyaluronic acid (HA) and hyaluronidase‐1 (HYAL‐1) levels in laryngeal cancer patients. Study design Prospective, controlled clinical trial. Setting University Medical Center. Participants Fifty laryngeal squamous cell carcinoma patients and 50 volunteers who gave saliva samples investigated prospectively between 2016 and 2017. Methods Hyaluronidase‐1 expression was measured by RT‐PCR in normal and tumour tissue samples; hyaluronic acid values of saliva and tumour tissues were measured by ELISA method. Results HYAL‐1 expression increased 2.5‐fold in tumour tissues compared to normal tissues, and the difference was statistically significant (P < 0.001).Mean saliva HA levels were 103.93 ± 69.04 ng/mL and 177.29 ± 98.44 ng/mL in the patients and controls’ saliva specimens, respectively. The difference was not statistically significant (P = 0.657). HA levels were higher in tumour tissue samples than saliva samples, but there was not statistically significant difference between saliva and tumour tissue HA levels. Conclusion HYAL‐1 expression in laryngeal squamous cell carcinomas is elevated compared to normal tissues of same patients. Targeting this gene and HA catabolism products may use treatment of larynx cancer in the future.

Hyaluronan as “Agent Smith” in cancer extracellular matrix pathobiology: Regulatory roles in immune response, cancer progression and targeting

“…22,23 In addition, in agreement with the accumulation of HA fragments, HYALs levels are also elevated in numerous cancer types. For instance, HYAL1 and HYAL2 are overexpressed and present elevated activity in bladder cancer, 23 larynx cancer, 24 breast cancer 25 and pancreatic ductal adenocarcinoma. 26 Cell migration-inducing and HA-binding protein (CEMIP, also known as KIAA1199 and HYBID), which is a mammalian HYAL, is also overexpressed in many types of cancer including ovarian, gastric, pancreatic ductal adenocarcinoma and non-small cell lung carcinoma [27][28][29][30] and correlated with poor survival.…”

Hyaluronidase-trigger nanocarriers for targeted delivery of anti-liver cancer compound

“…25 For example, hyaluronidase (HAase) is demonstrated with high expression levels in larynx cancer, bladder cancer, neck squamous cell, carcinoma cells, breast tumor, and liver cancer cells. [26][27][28][29][30][31] Thus, HAase overexpressed in cancer cells provide the basis for the targeted delivery of anticancer drugs. Besides, HAase plays an important role in the degradation of hyaluronic acid (HA), which is a glycosaminoglycan with the advantages of good biocompatibility and biodegradability, low toxicity, and nonimmunogenicity.…”